RESEARCH ARTICLE

Statins and the progression of age-related macular degeneration in the United States

Cassie A. Ludwig\textsuperscript{1,2}, Daniel Vail\textsuperscript{1}, Nitya A. Rajeshuni\textsuperscript{1}, Ahmad Al-Moujahed\textsuperscript{1}, Tatiana Rosenblatt\textsuperscript{1}, Natalia F. Callaway\textsuperscript{1}, Malini Veerappan Pasricha\textsuperscript{1}, Marco H. Ji\textsuperscript{1}, Darius M. Moshfeghi\textsuperscript{1,*}

\textsuperscript{1} Department of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, CA, United States of America, \textsuperscript{2} Department of Ophthalmology, Retina Service, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, United States of America

* dariusm@stanford.edu

Abstract

**Purpose**
To study the effect of statin exposure on the progression from non-exudative to exudative age-related macular degeneration (AMD).

**Methods**
Retrospective cohort study of commercially insured patients diagnosed with non-exudative AMD (n = 231,888) from 2007 to 2015. Time-to-event analysis of the association between exposure to lipid-lowering medications and time from non-exudative AMD to exudative AMD diagnosis was conducted. Outcome measures included progression to exudative AMD, indicated by diagnosis codes for exudative AMD or procedural codes for intravitreal injections.

**Results**
In the year before and after first AMD diagnosis, 11,330 patients were continuously prescribed lipid-lowering medications and 31,627 patients did not take any lipid-lowering medication. Of those taking statins, 21 (1.6%) patients were on very-high-dose lipophilic statins, 644 (47.6%) on high-dose lipophilic statins, and 689 (50.9%) on low-dose lipophilic statins. We found no statistically significant relationship between exposure to low (HR 0.89, 95% CI 0.83 to 1.38) or high-dose lipophilic statins (HR 1.12, 95% CI 0.86 to 1.45) and progression to exudative AMD. No patients taking very-high-dose lipophilic statins converted from non-exudative to exudative AMD, though this difference was not statistically significant due to the subgroup size (p = .23, log-rank test).

**Conclusions**
No statistically significant relationship was found between statin exposure and risk of AMD progression. Interestingly, no patients taking very-high-dose lipophilic statins progressed to exudative AMD, a finding that warrants further exploration.
stain molecule that among other things may be targeted for AMD. Additionally, Darius M. Moshfeghi has the following conflicts of interest: 1-800 Contacts (board of directors, equity), Akceso Advisors AG (evaluation of DME market), Akbeia (scientific advisory board for ROP), Alcon (data safety monitoring board for HAWK/HARRIER), Aldeyra Therapeutics (Site PI: ADX-2191-PVR-001 GUARD), Allegro (scientific advisory board, equity), Apellis (Site PI: APL2-303 DERBY), Bayer Pharma AG (ROP imaging committee), CMEOutfitters.com (CME consultant), Cole Eye Institute (CME consultant), Congruence medical solutions (consultant), dSentz, Inc (founder, board of directors, equity), Genentech (PROPER grant 2019), Grand Legend Technology, LTD (equity), Iconic Therapeutics (steering committee, unpaid), Irenix (scientific advisory board, unpaid), Northwest Health (grand rounds), Novartis Pharmaceuticals (data safety monitoring board for HAWK/HARRIER, KITE/KESTREL, China nAMD/DME, pediatric advisory board), Ocular Surgery News (consultant), Pr3vent (founder, board of directors, equity), Pykus (scientific advisory board, equity), Regeneron (CME consultant, ROP steering committee, PI for ROP trial), Retina Technologies LLC (advisor, consultant), Shapiro Law Group (ROP expert witness), SLACK, Inc. (founder, board of directors, equity), Vindico (CME consultant), University of Miami (CME consultant), Vist, Inc. (founder, equity), Vist, Inc. (founder, equity), Vindico (CME consultant), Visunex (scientific advisory board, equity). None of the other authors have any conflicts of interest to report. The above funders did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** Darius M. Moshfeghi is a co-founder with equity and serves on the board of directors of Linx, Inc a company that has developed a novel stain molecule that among other things may be targeted for AMD. Additionally, Darius M. Moshfeghi has the following conflicts of interest: 1-800 Contacts (board of directors, equity), Akceso Advisors AG (evaluation of DME market), Akbeia (scientific advisory board for ROP), Alcon (data safety monitoring board for HAWK/HARRIER), Aldeyra Therapeutics (Site PI: ADX-2191-PVR-001 GUARD), Allegro (scientific advisory board, equity), Apellis (Site PI: APL2-303 DERBY).

### Introduction

Age-related macular degeneration (AMD) is a neurodegenerative disease of the macula in which lipid-rich protein deposits accumulate between the retinal pigmented epithelium (RPE) and Bruch’s membrane (BrM). These lipid deposits interact with reactive oxygen species to form peroxidized lipids that either trigger the inflammatory pathway through upregulation of both cytokines and vascular endothelial growth factor (VEGF), which may lead to choroidal neovascularization, or cause toxicity to RPE cells leading to geographic atrophy [1–3].

While AMD ultimately results in neurodegeneration, AMD likely begins in the choroidal vasculature. The vascular model of macular degeneration posits that impairment of choroidal perfusion of the RPE leads to accumulation of lipoproteins in drusen and BrM [4]. Prior to the development of drusen, cholesterol accumulates in the same location suggesting its role in the pathogenesis of drusen and ultimately AMD [5]. AMD bears many similar risk factors to cardiovascular disease including age, smoking, obesity, hypertension, and atherosclerosis [6].

Since statins are a first-line therapy for hypercholesterolemia and coronary artery disease, statins may also aid in preventing or halting AMD pathogenesis [7].

As 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, the primary function of statins is to lower lipid levels by inhibiting the conversion of HMG-CoA into mevalonic acid, thereby inhibiting the production of isoprenoid intermediates of the biosynthetic cholesterol pathway [8]. Secondarily, statins have pleiotropic anti-inflammatory, anti-angiogenic, anti-thrombotic and antioxidant effects [9–13]. At present, the Age-Related Eye Disease Study (AREDS) vitamin formulation is the only intervention shown to prevent progression from non-exudative to exudative AMD and no treatment exists for geographic atrophy [14]. Given statins’ immunomodulatory and lipid-lowering effects, prior studies have examined their potential as therapy for non-exudative AMD with contradictory results [15–23]. These studies, however, have been limited by small numbers, a lack of stratified analysis of low- and high-dose statins, or limited or no control for confounders. We hypothesized that, after appropriate control for confounders available in the present database, patients with non-exudative AMD on very-high-dose lipophilic statins would have reduced progression to exudative AMD.

### Materials and methods

All data were fully anonymized before they were accessed for analysis. Institutional Review Board (IRB)/Ethics Committee ruled that approval was not required for this study.

### Study population

Patients were selected from the IBM MarketScan database, which includes administrative insurance data and prescription drug claims from 350 payers. Of the 123,637,719 commercially insured patients with outpatient encounters, 231,888 incident cases of non-exudative AMD occurred between 2008 and 2015. International Classification of Diseases (ICD) diagnostic codes versions 9 and 10 were used to identify diagnoses and FDA National Drug Codes (NDC) were used to identify prescriptions received and filled. Patients were included if they had a non-exudative AMD diagnosis (362.51, H35.31) and unchanged use of lipid-lowering medications (drug and dose) within a year of their index diagnosis. Early, intermediate, and advanced AMD stages were not distinguished, as the number of patients with ICD-10 coding was limited to 2015 to 2017. Exclusion criteria included patients with diabetes mellitus (250.00–250.93, E08-E13, O240-249), non-continuous database enrollment, <365 days of coverage preceding or following index non-exudative AMD diagnosis, lack of medication data, or evidence of exudative AMD diagnosis or related treatment (procedure code for intravitreal
injections) prior to diagnosis of non-exudative AMD. Patients were included in the control group if they had not taken a lipid-lowering medication within the year preceding or following their index non-exudative AMD diagnosis. Patients were included in the exposure group if they had a prescription for a lipid-lowering medication in both the year preceding and following their index diagnosis. Control group patients who began taking a lipid-lowering medication more than a year after their index diagnosis were censored from survival models at the date they began the medication. Similar methodology has previously been used to investigate the association between lipid-lowering medications and risk of diabetic retinopathy [24].

Outcomes
The primary outcome was progression to exudative AMD, as indicated by diagnosis codes for exudative AMD or procedural codes for intravitreal injections. The earliest diagnosis or procedural code indicating exudative AMD was used to measure time from non-exudative AMD diagnosis to exudative AMD diagnosis.

Exposures
To evaluate exposure to lipid-lowering medication prior to non-exudative AMD diagnosis, we coded individual medications using NDC numbers included in pharmaceutical records for each patient. Exposure was categorized based on use of any lipid-lowering medication, use of a statin, use of fibrates (fenofibrate, gemfibrozil), or concomitant use of both statins and fibrates. Statin exposure was further divided into hydrophilic statins (rosuvastatin, pravastatin) versus lipophilic statins (simvastatin, lovastatin, atorvastatin, fluvastatin, pitavastatin) [25, 26], with the latter category characterized based on dosage: 1) very-high-dose lipophilic statins (atorvastatin 80 mg) [23], 2) high-dose lipophilic statins (atorvastatin 20–40 mg, simvastatin 40–80 mg, pitavastatin 2–4 mg) [17], 3) low-dose lipophilic statins (atorvastatin 10 mg, simvastatin 5–20 mg, fluvastatin 20–80 mg, lovastatin 10–80 mg, pitavastatin 1 mg) [27].

Covariates
We adjusted for comorbidities associated with exudative AMD risk and with use of a lipid-lowering medication, including age at index non-exudative AMD diagnosis, sex, smoking, and a vector of comorbidities drawn from the Elixhauser Comorbidity Index [28]. Additionally, we adjusted for baseline use of certain medications prior to index diagnosis that indicated a more complicated cardiovascular history (anticoagulants, antihypertensive medications, or diuretics).

Statistical analysis
All data were analyzed using Stata 14.2 (StataCorp, College Station, TX, US). We conducted time-to-event analysis of the association between exposure to lipid-lowering medications and time from diagnosis of non-exudative AMD to diagnosis of exudative AMD. We estimated Cox proportional hazards models for time to first diagnosis of exudative AMD and time to first intravitreal injection, including unadjusted and adjusted models using the aforementioned covariates. We also performed a sensitivity analysis using Cox proportional hazards models with propensity score matching and restriction of the sample to the region of common support (with inverse probability weighting).
Results
We identified 231,888 patients with a diagnosis of non-exudative AMD, of whom 42,957 met criteria for analysis (S1 Fig). Demographic data is included in Table 1. Patients were started on lipid-lowering medications at an average age of 47 years (SD 2.1 years). Patients taking lipid-lowering medications were less likely to be female (51.2%) than those not taking lipid-lowering medications (63.6%, p < .001) and were more likely to be current or former smokers (5.9% vs. 4.5%, p < .001), had a higher average Elixhauser comorbidity index (2.2 vs. 1.5, p < .001), and were more likely to be taking an anticoagulant (3.2% vs. 1.6%, p < .001), antihypertensive (49.1% vs. 19.2%, p < .001), or diuretic (17.7% vs. 8.5%, p < .001).

Table 1. Characteristics: Baseline characteristics of patients diagnosed with non-exudative age-related macular degeneration between 2008 to 2015.

| Characteristics | No lipid-lowering medication | Lipid-lowering medication | P Value |
|-----------------|------------------------------|---------------------------|---------|
| Age at diagnosis (mean, SD) | 46.6 (2.1) | 46.4 (2.1) | < .001 |
| Female | 20,125 (63.6) | 5,800 (19.2) | < .001 |
| Smoker | 1,408 (4.5) | 672 (5.9) | < .001 |
| Years follow-up (mean, SD) | 3.1 (1.7) | 2.9 (1.6) | < .001 |
| Total Elixhauser comorbidities (mean, SD) | 1.5 (1.6) | 2.2 (1.8) | < .001 |
| On anticoagulation | 512 (1.6) | 366 (3.2) | < .001 |
| On antihypertensive medication | 6,085 (19.2) | 5,566 (49.1) | < .001 |
| On diuretics | 2,702 (8.5) | 2,001 (17.7) | < .001 |

Exposure to Lipid-Lowering Medications
- Any lipid-lowering medication | 11,330 (100) |
- Statin | 9,211 (81.3) |
- Fibrates | 453 (4.0) |
- Simultaneous statin and fibrates | 192 (1.7) |

Exposure to Statins by Lipophilic-Hydrophilic Balance
- Lipophilic statins | 6,731 (59.4) |
- Hydrophilic statins | 2,353 (20.8) |

Exposure to Statins by Class
- Very high dose lipophilic statin | 21 (1.6) |
- High dose lipophilic statin | 644 (47.6) |
- Low dose lipophilic statin | 689 (50.9) |

Exposure to Statins by Drug
- Simvastatin (lipophilic) | 3,725 (41.7) |
- Lovastatin (lipophilic) | 318 (3.6) |
- Atorvastatin (lipophilic) | 2,515 (28.2) |
- Fluvastatin (lipophilic) | 24 (0.3) |
- Pitavastatin (lipophilic) | 16 (0.2) |
- Rosuvastatin (hydrophilic) | 1,305 (14.6) |
- Pravastatin (hydrophilic) | 1,026 (11.5) |

Outcomes
- Exudative macular degeneration | 1,012 (3.2) |
- Anti-VEGF injection | 2,004 (6.3) |

SD = standard deviation; VEGF = vascular endothelial growth factor.
*Percentage of all patients on statins with NDC coding including dosing.
In order from most to least lipophilic.
**Percentage of all patients on non-combination statins.

https://doi.org/10.1371/journal.pone.0252878.t001
Of the 11,330 patients taking a lipid-lowering medication, 9,211 (81.3%) were taking a statin, 453 (4.0%) a fibrate, and 192 (1.7%) both a statin and fibrate. Of those taking statins, NDC coding included dosing for 1,354 patients (14.7%): 21 (1.6%) took very-high-dose lipophilic statins, 644 (47.6%) took high-dose statins, and 689 (50.9%) took low-dose statins. Most patients were prescribed lipophilic statins, with 3,725 of 8,929 patients (41.7%) on simvastatin, 2,515 (28.2%) on atorvastatin, 318 (3.6%) on lovastatin, 24 (0.3%) on fluvastatin, and 16 (0.2%) on pitavastatin. Of those taking a hydrophilic statin, the majority took rosvastatin (n = 1,305, 14.6%) compared to pravastatin (n = 1,026, 11.5%).

**Progression from non-exudative to exudative macular degeneration**

Overall, 8.3% (n = 945) of patients on lipid-lowering medications had a diagnosis code for exudative AMD or a procedural code for anti-VEGF injections following non-exudative AMD diagnosis, compared to 7.9% (n = 2,483) of patients who did not take lipid-lowering medications (p = .099). Average follow-up time was 1,066 days (SD 590 days) for those on lipid-lowering medications compared to 1,130 days (SD 632 days) for those not on lipid-lowering medications. In total, 3,079 patients were censored from our analysis as they eventually began taking a lipid-lowering medication. Among the control group, average time from diagnosis of non-exudative AMD to first lipid-lowering prescription was 930 days (SD 518 days).

We found no significant difference in progression to exudative AMD or risk of receiving an anti-VEGF injection in patients who took lipid-lowering medications prior to diagnosis after adjusting for age at index diagnosis of non-exudative AMD, sex, smoking, comorbidities from the Elixhauser Comorbidity Index, and use of anticoagulants, antihypertensives, or diuretics (Fig 1). Similarly, no significant differences were found in progression to exudative AMD in those taking lipophilic statins (HR 1.03, 95% CI 0.90–1.19) or hydrophilic statins (HR 0.98, 95% CI 0.77–1.23).

We found no statistically significant subgroup, though no patients taking very-high-dose statins converted to exudative AMD (not shown here, as hazard ratios could not be calculated).

None of the patients taking very-high-dose lipophilic statins prior to non-exudative AMD diagnosis progressed to exudative AMD or required an anti-VEGF injection (p = .23, log-rank test). We found no statistical difference in risk of exudative AMD in those taking high-dose lipophilic statins (HR 1.12, 95% CI 0.86 to 1.45), low-dose lipophilic statins (HR 1.07, 95% CI 0.83 to 1.38), fibrates alone (HR 1.13, 95% CI 0.83 to 1.55), or both statins and fibrates (HR 1.18, 95% CI 0.73 to 1.91).

Unadjusted Cox models demonstrated a non-significantly increased risk of progression to exudative AMD and of anti-VEGF injection among patients on lipid-lowering medications, as well as among all subgroups with the exception of patients on fibrates and hydrophilic statins (S2 Fig). Similar outcomes were found with models that adjusted for patient attributes using matching based on propensity scores (S3 Fig). Unadjusted Kaplan-Meier curves of the progression to exudative AMD from time of index non-exudative AMD diagnosis, stratified by statin dose (Fig 2) and statin properties (Fig 3), illustrate the findings discussed above, with no progression to non-exudative AMD among patients on very-high-dose lipophilic statins.

All of these patients had a very-high-dose statin prescription that was unchanged within a year of their index non-exudative AMD diagnosis. Average follow-up time was 2.3 years (SD 1.0 years). In these unadjusted Kaplan-Meier curves there was no significant difference in progression to exudative AMD for patients taking high-dose lipophilic statins (simvastatin 40 mg to simvastatin 80 mg or equivalent) or low-dose lipophilic statins (statin dose lower than simvastatin 40mg or equivalent).
Average follow-up time for patients using hydrophilic and lipophilic statins was 2.8 years (SD 1.5 years) and 2.9 years (SD 1.6 years) respectively. In these unadjusted Kaplan-Meier curves there was no significant difference in progression to exudative AMD for patients taking lipophilic or hydrophilic statins compared to no lipid-lowering medications.

Discussion

This is the largest observational study to specifically examine the effect of lipophilic statin dosage on progression to exudative AMD. In accordance with the findings of Vavvas et al. we found that no patients taking very-high-dose lipophilic statins converted from non-exudative to exudative AMD despite an expected incidence of 1 to 2 patients, though this finding was not statistically significant [23]. We found no significant relationship between exposure to high-dose or low-dose lipophilic statins and progression to exudative AMD, nor did we find a difference in AMD progression between lipophilic and hydrophilic statins despite their relative pharmacokinetic differences [25].

Prior studies on the relationship between statins and AMD have yielded heterogeneous results. Hall et al. were the first to propose a beneficial ophthalmic effect of statins in 2001 in a cross-sectional study of 660 patients, in which they found a 0.14 OR of AMD among the 379 statins users [18]. Similarly, a lower rate of progression of early AMD among statin users compared to non-statin users (3.6% vs. 13.0%) was subsequently reported in a study of 4,345 patients, though the effect was not statistically significant [20]. A nested case-control single-site study found that early AMD cases (n = 550) were 70% less likely to have received and filled
Fig 2. Time to progression from non-exudative to exudative age-related macular degeneration (AMD) by dose of lipophilic statin. No patients taking very-high-dose lipophilic statins (atorvastatin 80 mg) converted from non-exudative to exudative AMD.

https://doi.org/10.1371/journal.pone.0252878.g002

Fig 3. Time to progression from non-exudative to exudative age-related macular degeneration (AMD) by class of statin.

https://doi.org/10.1371/journal.pone.0252878.g003
a statin prescription than the 5,500 matched controls [29]. Two recent prospective clinical trials demonstrated a beneficial effect of lipophilic statins in non-exudative AMD [17, 23]; a prospective, double-masked trial of 114 patients randomized to simvastatin 40 mg (equivalent to our high-dose lipophilic statin group) versus placebo for three years found a significantly lower rate of AMD progression (54%) in the simvastatin group compared to the placebo group (70%), with a greater effect seen in the intermediate AMD group and those with the CFH genotype (Y402H) and no effect found in advanced AMD patients. A subsequent open-label prospective controlled trial of 24 AMD patients on atorvastatin 80 mg daily (equivalent to our very-high-dose lipophilic statin group) for one year found regression of large soft drusen and PEDs among 43.5% of patients at 1.5 year follow-up, with significant improvement in visual acuity among treatment responders compared to non-responders [23].

Despite these aforementioned studies suggesting a benefit of statins in AMD, we found no significant effect of statins on the progression of AMD, a finding supported by several prior population-based cohort and case-control studies [19, 21, 30–32]. The largest of these prior studies was a national claims database analysis of 10,753 patients with non-exudative AMD, in which a higher risk of progression from non-exudative to exudative AMD was found in those who used statins longer, though a lower risk of progression in those with normalized LDL and higher risk of progression in those with high HDL. A retrospective cohort study and a large prospective cohort study within AREDS2 similarly found no effect of statins on advanced AMD and on progression to late AMD, respectively [15, 33]. Systematic, non-systematic, and narrative reviews have all found insufficient evidence to conclude that statins have a role in preventing or delaying progression of AMD [6, 16, 34–36].

Strengths of our study include analysis of lipophilic statin exposure stratified by dosage, a distinction that has not been made in previous observational studies, and its strict control for confounders available within the database. Limitations include those inherent to database studies including the use of ICD coding, which is performed by physicians for billing purposes and may not accurately capture all pathology. More specifically, this study is limited by the inclusion of ICD-9 coding, which does not discriminate between stages of non-exudative or stages of exudative AMD and is therefore unable to capture potential variations in the statins’ effects in early and advanced AMD [34]. Differentiation of stages will be critical to determine timing of a possible primary prevention. This study is additionally limited by the use of NDC coding, as a statin prescription does not necessarily imply statin use. Furthermore, the total number of patients with NDC coding for a statin that included dose was significantly lower than the total number of patients taking statins leading to the potential for ascertainment bias. Lastly, following strict inclusion and exclusion criteria, the final cohort of patients taking very high dose statins was small. A prospective controlled study is required to evaluate dose response while controlling more accurately for risk factors unavailable in this data set (race/ethnicity, lipid profile, use of non-prescription AREDS2 formulations, basal metabolic rate) that may lead to residual confounding. Long duration of follow up in a prospective trial would be critical to determine the efficacy of very-high-dose lipophilic statins in preventing progression.

With a predicted 288 million people who will be affected by AMD by 2040, it is critical that we develop new means by which to prevent and treat AMD [37]. Although not statistically significant, we found that patients taking very-high-dose lipophilic statins did not progress to exudative AMD nor require anti-VEGF therapy over an average follow-up of 2.3 years. These results add to the growing body of research supporting a possible role for very-high-dose lipophilic statin therapy in preventing progression of non-exudative AMD, warranting further study. Future studies will benefit from additional ICD-10 classifiers of AMD to distinguish progression from earlier to advanced forms of non-exudative and exudative AMD.
Supporting information

S1 Fig. Exclusion criteria. Graphic representation of exclusion criteria applied to build final analytic sample. (TIFF)

S2 Fig. Forest plot of unadjusted cox proportional hazards models. Forest plot demonstrating unadjusted cox proportional hazards models of patients exposed to lipid-lowering medications and their progression to exudative AMD and/or need for treatment with anti-VEGF medication. (TIFF)

S3 Fig. Forest plot of adjusted cox proportional hazards models using propensity score matching. Forest plot demonstrating adjusted cox proportional hazards models using propensity score matching of patients exposed to lipid-lowering medications and their progression to exudative AMD and/or need for treatment with anti-VEGF medication. (TIFF)

Author Contributions

Conceptualization: Cassie A. Ludwig, Daniel Vail, Nitya A. Rajeshuni, Natalia F. Callaway, Darius M. Moshfeghi.

Data curation: Daniel Vail.

Formal analysis: Cassie A. Ludwig, Daniel Vail.

Investigation: Cassie A. Ludwig, Nitya A. Rajeshuni, Darius M. Moshfeghi.

Methodology: Cassie A. Ludwig, Ahmad Al-Moujahed, Darius M. Moshfeghi.

Project administration: Ahmad Al-Moujahed.

Resources: Tatiana Rosenblatt.

Supervision: Darius M. Moshfeghi.

Writing – original draft: Cassie A. Ludwig.

Writing – review & editing: Cassie A. Ludwig, Daniel Vail, Nitya A. Rajeshuni, Ahmad Al-Moujahed, Tatiana Rosenblatt, Natalia F. Callaway, Malini Veerappan Pasricha, Marco H. Ji, Darius M. Moshfeghi.

References

1. Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018; 392: 1147–1159. https://doi.org/10.1016/S0140-6736(18)31550-2 PMID: 30303083

2. Rozing MP, Durhuus JA, Krogh Nielsen M, Subhi Y, Kirkwood TB, Westendorp RG, et al. Age-related macular degeneration: A two-level model hypothesis. Prog Retin Eye Res. 2020; 76: 100825. https://doi.org/10.1016/j.preteyeres.2019.100825 PMID: 31899290

3. Behnke V, Wolf A, Langmarr T. The role of lymphocytes and phagocytes in age-related macular degeneration (AMD). Cell Mol Life Sci. 2020; 77: 781–788. https://doi.org/10.1007/s00018-019-03419-4 PMID: 31897541

4. Friedman E. Update of the vascular model of AMD. Br J Ophthalmol. 2004; 88: 161–163. https://doi.org/10.1136/bjo.2003.068277 PMID: 14736760

5. Curcio CA, Johnson M, Huang J-D, Rudolf M. Apolipoprotein B-containing lipoproteins in retinal aging and age-related macular degeneration. J Lipid Res. 2009/09/29 ed. 2010; 51: 451–467. https://doi.org/10.1194/jlr.R002238 PMID: 19797256
6. Tsao SW, Fong DS. Do Statins Have a Role in the Prevention of Age-Related Macular Degeneration? Drugs & Aging. 2013; 30: 205–213. https://doi.org/10.1007/s40266-013-0061-4 PMID: 23423861
7. van Leeuwen EM, Emri E, Merle BMJ, Colijn JM, Kersten E, Cougnard-Gregoire A, et al. A new perspective on lipid research in age-related macular degeneration. Prog Retin Eye Res. 2018; 67: 56–86. https://doi.org/10.1016/j.preteyeres.2018.04.006 PMID: 29729972
8. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990; 343: 425–430. https://doi.org/10.1038/343425a0 PMID: 28971147
9. Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis. 2009; 203: 325–330. https://doi.org/10.1016/j.atherosclerosis.2008.08.022 PMID: 18834985
10. Miyaki K, Matsubara A, Nishiwaki A, Tomida K, Morita H, Yoshida M, et al. Pitavastatin Attenuates Leukocyte-Endothelial Interactions Induced by Ischemia-Reperfusion Injury in the Rat Retina. Current Eye Research. 2009; 34: 10–17. https://doi.org/10.1080/02713680802579196 PMID: 19172465
11. Penfold PL, Madigan MC, Gillies MC, Provis JM. Immunologic and Aetiological Aspects of Macular Degeneration. Progress in Retinal and Eye Research. 2001; 20: 385–414. https://doi.org/10.1016/s1350-9462(00)00025-2 PMID: 11286898
12. Terai N, Sperel E, Fischer S, Hornykewycz K, Haustein M, Haentzel J, et al. Statins affect ocular microcirculation in patients with hypercholesterolaemia. Acta Ophthalmologica. 2011; 89: e500–e504. https://doi.org/10.1111/j.1755-3768.2011.02154.x PMID: 21457486
13. Tsujinaka H, Itaya-Hironaka A, Yamazaki A, Sakuramoto-Tsuchida S, Shobatake R, Makino M, et al. Statins decrease vascular epithelial growth factor expression via down-regulation of receptor for advanced glycation end-products. Heliyon. 2017; 3: e00401–e00401. https://doi.org/10.1016/j.heliyon.2017.e00401 PMID: 28911147
14. Age-Related Eye Disease Study Research Group. A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss. Archives of Ophthalmology. 2001; 119: 1417. https://doi.org/10.1001/archophtha.2015.08.028 PMID: 26435335
15. Al-Holou SN, Tucker WR, Agro´n E, Clemons TE, Cukras C, Ferris FL 3rd, et al. The Association of Statin Use with Age-Related Macular Degeneration Progression: The Age-Related Eye Disease Study 2 Report Number 9. Ophthalmology. 2015/10/04 ed. 2015; 122: 2490–2496. https://doi.org/10.1016/j.ophtha.2015.08.028 PMID: 26435335
16. Gehbich P, Li T, Hatfei E. Statins for age-related macular degeneration. Cochrane Database Syst Rev. 2016; CD006927–CD006927. https://doi.org/10.1002/14651858.CD006927.pub5 PMID: 27490232
17. Guymer RH, Baird PN, Varsamidis M, Busija L, Dimitrov PN, Aung KZ, et al. Proof of concept, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration. PLoS One. 2013; 8: e83759–e83759. https://doi.org/10.1371/journal.pone.0083759 PMID: 24391822
18. Hall NF, Gale CR, Syddall H, Phillips DI, Martyn CN. Risk of macular degeneration in users of statins: cross sectional study. BMJ. 2001; 323: 375–376. https://doi.org/10.1136/bmj.323.7309.375 PMID: 11509429
19. Klein R, Klein B, Tomany S, Danforth L, Cruickshanks K. Relation of Statin Use to the 5-Year Incidence and Progression of Age-Related Maculopathy, Archives of Ophthalmology. 2003; 121: 1151. https://doi.org/10.1001/archophtha.121.8.1151 PMID: 12912693
20. McCarty CA, Mukesh BN, Guymer RH, Baird PN, Taylor HR. Cholesterol-lowering medications reduce the risk of age-related maculopathy progression. Medical Journal of Australia. 2001; 175: 349–350. https://doi.org/10.5694/j.1326-5377.2001.tb143604.x PMID: 11665992
21. Klein R, Knudtson MD, Klein BEK. Statin use and the five-year incidence and progression of age-related macular degeneration. Am J Ophthalmol. 2007/05/02 ed. 2007; 144: 1–6. https://doi.org/10.1016/j.ajo.2007.02.047 PMID: 17475196
22. VanderBeek BL, Zacks DN, Tailwar N, Nan B, Stein JD. Role of statins in the development and progression of age-related macular degeneration. Retina. 2013; 33: 414–422. https://doi.org/10.1097/IAE.0b013e318276e0cf PMID: 23314233
23. Vavvas DG, Daniels AB, Kapsala ZG, Goldfarb JW, Ganotakis E, Loewenstein JI, et al. Regression of Some High-risk Features of Age-Related Macular Degeneration (AMD) in Patients Receiving Intensive Statin Treatment. EBioMedicine. 2016; 5: 198–203. https://doi.org/10.1016/j.ebiom.2016.01.033 PMID: 27077128
24. Vail D, Callaway NF, Ludwig CA, Saroj N, Moshfeghi DM. Lipid-Lowering Medications Are Associated with Lower Risk of Retinopathy and Ophthalmic Interventions among United States Patients with Diabes. American Journal of Ophthalmology. 2019; 207: 378–384. https://doi.org/10.1016/j.ajo.2019.05.029 PMID: 31194953
25. Fong CW. Statins in therapy: Understanding their hydrophilicity, lipophilicity, binding to 3-hydroxy-3-methylglutaryl-CoA reductase, ability to cross the blood brain barrier and metabolic stability based on electrostatic molecular orbital studies. European Journal of Medicinal Chemistry. 2014; 85: 661–674. https://doi.org/10.1016/j.ejmech.2014.08.037 PMID: 25128668

26. Wu T, Fujihara M, Tian J, Jovanovic M, Grayson C, Cano M, et al. Apolipoprotein B100 secretion by cultured ARPE-19 cells is modulated by alteration of cholesterol levels. J Neurochem. 2010/07/27 ed. 2010; 114: 1734–1744. https://doi.org/10.1111/j.1471-4159.2010.06884.x PMID: 20598021

27. Smith MB, Lee NJ, Haney E, Carson S. Drug Class Review: HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin: Final Report Update 5 [Internet]. In: Drug Class Review: HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin: Final Report Update 5 [Internet] [Internet]. Nov 2009 [cited 12 May 2020]. Available: https://www.ncbi.nlm.nih.gov/books/NBK47280/

28. Menendez ME, Neuhaus V, van Dijk CN, Ring D. The Elixhauser comorbidity method outperforms the Charlson index in predicting inpatient death after orthopaedic surgery. Clin Orthop Relat Res. 2014/05/28 ed. 2014; 472: 2878–2886. https://doi.org/10.1007/s11999-014-3886-7 PMID: 24867450

29. McGwin G, Owseley C, Curcio CA, Crain RJ. The association between statin use and age related maculopathy. American Journal of Ophthalmology. 2004; 137: 217. https://doi.org/10.1016/j.ajo.2003.10.014

30. Fong DS, Contreras R. Recent Statin Use and 1-Year Incidence of Exudative Age-Related Macular Degeneration. American Journal of Ophthalmology. 2010; 149: 955–958.e1. https://doi.org/10.1016/j.ajo.2009.12.037 PMID: 20346349

31. Shalev V, Sror M, Goldshtein I, Kokia E, Chodick G. Statin Use and the Risk of Age Related Macular Degeneration in a Large Health Organization in Israel. Ophthalmic Epidemiology. 2011; 18: 83–90. https://doi.org/10.3109/09286586.2011.560746 PMID: 21401416

32. Smeeth L, Cook C, Chakravarthy U, Hubbard R, Fletcher AE. A case control study of age related macular degeneration and use of statins. American Journal of Ophthalmology. 2006; 141: 238. https://doi.org/10.1016/j.ajo.2005.11.029

33. Maguire MG, Ying G, McCannel CA, Liu C, Dai Y, Complications of Age-related Macular Degeneration Prevention Trial (CAPT) Research Group. Statin use and the incidence of advanced age-related macular degeneration in the Complications of Age-related Macular Degeneration Prevention Trial. Ophthalmology. 2009; 116: 2381–2385. https://doi.org/10.1016/j.ophtha.2009.06.055 PMID: 19850347

34. Ma L, Wang Y, Du J, Wang M, Zhang R, Fu Y. The association between statin use and risk of age-related macular degeneration. Sci Rep. 2015; 5: 18280–18280. https://doi.org/10.1038/srep18280 PMID: 26658620

35. Peponis V, Chalkiadakis SE, Bonovas S, Sitaras NM. The controversy over the association between statins use and progression of age-related macular degeneration: a mini review. Clin Ophthalmol. 2010; 4: 865–869. https://doi.org/10.2147/ophth.s12866 PMID: 20714364

36. Waugh N, Loveman E, Colquitt J, Royle P, Yeong JL, Hoad G, et al. Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review. Health Technol Assess. 2018; 22: 1–168. https://doi.org/10.3310/hta22270 PMID: 29846169

37. Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng C-Y, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. The Lancet Global Health. 2014; 2: e106–e116. https://doi.org/10.1016/S2214-109X(13)70145-1 PMID: 25104651